Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2

Status

Completed 4

Sponsor Class

NIH 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 17Sarcoma 13Lymphoid 11Gynecologic 9CNS 6Tumor-Agnostic 4Other hematologic neoplasm 4Breast 4Head & Neck 3Gastrointestinal 3Dermatologic 3Thoracic 2Plasma cell 1Other solid neoplasm 1

Conditions

Breast Neoplasms 4Neoplasms 1Breast Neoplasms, Male 1

Interventions

Trastuzumab 260Paclitaxel 216Cyclophosphamide 173Docetaxel 146Letrozole 126Fulvestrant 121Capecitabine 121Doxorubicin 111Carboplatin 98Bevacizumab 90exemestane 88Anastrozole 85Tamoxifen 77Lapatinib 77pembrolizumab 68Albumin-Bound Paclitaxel 67pertuzumab 62palbociclib 60Taxes 59Gemcitabine 57eribulin 48130-nm albumin-bound paclitaxel 47Radiotherapy 46Everolimus 44Ado-Trastuzumab Emtansine 43Vinorelbine 39ixabepilone 32Epirubicin 30Cisplatin 30pegfilgrastim 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has results × temsirolimus × Breast × Clear all
NCT00376688 2020-02-24

Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast Cancer

National Cancer Institute (NCI)

Phase 2 Completed
31 enrolled 5 charts
Breast

Breast Neoplasms

NCT01111825 2018-09-26

Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer

Puma Biotechnology, Inc.

Phase 1/2 Completed
99 enrolled 14 charts
Breast

Breast Neoplasms

NCT00699491 2018-06-13

Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
48 enrolled 14 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00062751 2011-04-15

Study Evaluating Temsirolimus (CCI-779) In Breast Neoplasms

Wyeth is now a wholly owned subsidiary of Pfizer

Phase 2 Completed
108 enrolled 4 charts
Breast

Breast Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡